Marker Therapeutics, Inc.

As of June 30, 2026, Marker Therapeutics, Inc. carries a market capitalization of 21.01M, placing it among publicly traded companies globally. Its enterprise value stands at 11.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Marker Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Marker Therapeutics, Inc. has 16.67M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Marker Therapeutics, Inc. maintains a current ratio of 6.03, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Marker Therapeutics, Inc. posted a negative return on equity (ROE) of -76.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -59.33, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 5.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Marker Therapeutics, Inc.'s stock has gained approximately 21.18% over the past 52 weeks. The 50-day moving average sits at 1.04, while the 200-day moving average is 1.20.

Over the twelve months ended June 30, 2026, Marker Therapeutics, Inc. generated - - in revenue and converted that into -7.62M in net income, yielding earnings per share of -0.42. EBITDA reached -9.38M, while operating income came in at -8.12M.

These figures are as of June 30, 2026. Total book value stands at 10.65M, with working capital of 10.65M providing operational flexibility.

Marker Therapeutics, Inc. produced -8.54M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -37.62: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -41.10, meaning Marker Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Marker Therapeutics, Inc.'s most recent stock split took place on January 27, 2023 with a 10:1 split ratio.

As of June 30, 2026, Marker Therapeutics, Inc. has an Altman Z-Score of -39.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.